Economics of Access to Medicines: The Challenges of Pharmaceutical Patents,...
While it is easy to point to patents and blame the industry and international trade agreements for barriers to access to medicines in developing nations, the reality of the situation is more nuanced...
View ArticleAre Pharmaceutical Patents A Barrier to Access to Medicines? The Importance...
Critics argue that pharmaceutical patents are a barrier to wide-reaching access to medicines, especially for vulnerable populations in the developing world. They cast their argument in the phrase,...
View ArticleWhat happens to IP law in 2014?
I prophesy that the best we can hope for is a Bilski-esque vague instruction (wherein our top court opined that some business methods are patentable, citing the machine or transformation test as one...
View ArticleThe Sticking Point that Shouldn’t Be: The Role of Pharmaceutical Patents in...
The controversy swirling around the Trans-Pacific Partnership (TPP) Trade Agreement sheds light on two critically important but divisive issues: international trade and intellectual property protection...
View ArticleThe Need for Regulatory Data Protection in the TPP: Why Australia’s Got it...
While patents protect innovations that are novel, nonobvious and useful, data exclusivity protects the extensive preclinical and clinical trial data required to establish new therapies as safe and...
View ArticleTrans-Pacific Partnership – What do IP practitioners need to know?
Trade partners negotiating the Tans-Pacific Partnership trade deal have reached an agreement. The agreement details have not been released, and likely will not be submitted to Congress for a mandatory...
View ArticleIP Protection for Biologics in the TPP: Trading Away Future Treatments and Cures
Globally there are approximately 7,000 medicines in development to treat and cure a wide variety of diseases. Of these, more than 5,000 are in development in the United States. It’s difficult to argue...
View ArticleTPP and Protection of Encrypted Program-Carrying Satellite and Cable Signals
It is already a criminal act in the United States to intercept and/or decode an encrypted satellite signal. See 18 U.S.C. §2511. Many in the United States may not realize that similar provisions...
View ArticleTPP: What the Government Use of Software Provisions Mean
The language of the Trans-Pacific Partnership’s ostensible provision on Government Use of Software (Article QQ.H.11) is short and relatively straight-forward. This article examines the Trans-Pacific...
View ArticlePatents, Innovation and the Presidential Candidates
Patents, intellectual property, innovation and technology policy may not decide who will become the next President of the United States, but the positions the candidates hold will greatly impact the...
View ArticlePatently Trump: Can He Do a Better Job Enforcing American Innovations?
Now it is time for Trump to call for a vigorous debate on the Trans Pacific Partnership Treaty (“TPP”) to demonstrate his expertise on matters of strategic national and international economic...
View ArticleClinical Trials and Tribulations: Why IP Protection is Critical to the Future...
Given the importance of intellectual property rights to economic growth and technological development, as well as the wider benefits of biopharmaceutical research, the provisions found in the recently...
View ArticleKeystone XL, Dakota Access prove pipelines have advanced way beyond wooden...
Nearly 150 years of development in the field has been supported by both the commercial success of the pipeline concept as well as the incredible importance that fossil fuels have in powering our modern...
View ArticleEconomics of Access to Medicines: The Challenges of Pharmaceutical Patents,...
While it is easy to point to patents and blame the industry and international trade agreements for barriers to access to medicines in developing nations, the reality of the situation is more nuanced...
View ArticleAre Pharmaceutical Patents A Barrier to Access to Medicines? The Importance...
Critics argue that pharmaceutical patents are a barrier to wide-reaching access to medicines, especially for vulnerable populations in the developing world. They cast their argument in the phrase,...
View ArticleWhat happens to IP law in 2014?
I prophesy that the best we can hope for is a Bilski-esque vague instruction (wherein our top court opined that some business methods are patentable, citing the machine or transformation test as one...
View ArticleThe Sticking Point that Shouldn’t Be: The Role of Pharmaceutical Patents in...
The controversy swirling around the Trans-Pacific Partnership (TPP) Trade Agreement sheds light on two critically important but divisive issues: international trade and intellectual property protection...
View ArticleThe Need for Regulatory Data Protection in the TPP: Why Australia’s Got it...
While patents protect innovations that are novel, nonobvious and useful, data exclusivity protects the extensive preclinical and clinical trial data required to establish new therapies as safe and...
View ArticleTrans-Pacific Partnership – What do IP practitioners need to know?
Trade partners negotiating the Tans-Pacific Partnership trade deal have reached an agreement. The agreement details have not been released, and likely will not be submitted to Congress for a mandatory...
View ArticleIP Protection for Biologics in the TPP: Trading Away Future Treatments and Cures
Globally there are approximately 7,000 medicines in development to treat and cure a wide variety of diseases. Of these, more than 5,000 are in development in the United States. It’s difficult to argue...
View Article
